EUVIMEDObjevte EUVIMED
Open access

Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City

Ofole Mgbako, Monica Mehta, Donald Dietz, Matthew J Neidell, Simian Esther Huang, Jason Zucker, Sherif Shoucri, Christine J Kubin, Delivette Castor

Ethnicity and Disease · 2023

DOI: 10.18865/1653 ↗

At a glance

Journal article in Ethnicity and Disease, 2023. Written by Ofole Mgbako and 8 co-authors. Institution: Division of Infectious Diseases, Department of Medicine, NYU Langone Health, New York, NY. Major MEDLINE topics: Adenosine Monophosphate, Alanine, Antiviral Agents, COVID-19 Drug Treatment. Cited 2 times so far (Crossref); 21 references. The full text is freely available in PubMed Central. Funded by: NIMH NIH HHS, NIAID NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To compare clinical characteristics and examine in-hospital length of stay (LOS) differences for COVID-19 patients who received remdesivir, by race or ethnicity.

Design

Retrospective descriptive analysis comparing cumulative LOS as a proxy of recovery time.

Setting

A large academic medical center serving a minoritized community in Northern Manhattan, New York City.

Participants

Inpatients (N=1024) who received remdesivir from March 30, 2020–April 20, 2021.

Methods

We conducted descriptive analyses among patients who received remdesivir. Patients were described by proxies of social determinants of health (SDOH): race and ethnicity, residence, insurance coverage, and clinical characteristics. We calculated median hospital LOS as the cumulative incidence of hospitalized patients who were discharged alive, and tested differences between groups by using the Gray test. Patients who died or were discharged to hospice were censored at 29 days. Main Outcome Measures The primary outcome was hospital LOS. The secondary outcome was in-hospital mortality.

Results

Median LOS was 11.9 days (95% CI, 10.8-13.2) overall, with Black patients having the shortest (10.0 days, 95% CI, 8.0-13.2) and Asian patients having the longest (16.2 days, 95% CI, 8.3-27.2) LOS. A total of 214 patients (21%) died or were discharged to hospice, ranging from 16.5% to 23.7% of patients who identified as Black and Other (multiracial, biracial, declined), respectively.

Conclusions

COVID-19 has disproportionately burdened communities of color. We observed no difference in median LOS between racial or ethnic groups, which supports the notion that the heterogeneous effect of remdesivir in the literature may be explained in part by underrecruitment or participation of Black, Hispanic, and Asian patients in clinical trials.

Subjects

MeSH terms (MEDLINE)

Adenosine MonophosphateAlanineAntiviral AgentsCOVID-19 Drug TreatmentLength of StayAdultAgedFemaleHumansMaleMiddle AgedBlack or African AmericanCOVID-19Hospital MortalityNew York CityRetrospective StudiesSARS-CoV-2Treatment OutcomeAsianRacial GroupsHispanic or Latino

Author keywords

COVID-19EthnicityLength of StayRaceRemdesivir

Substances

Adenosine MonophosphateAlanineAntiviral Agentsremdesivir

Authors and institutions

  • Division of Infectious Diseases, Department of Medicine, NYU Langone Health, New York, NY.
  • NYU Institute for Excellence in Health Equity, NYU Langone Health, New York, NY.
  • Department of Pharmacy, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY.
  • Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY.
  • Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY.

Funding

  • NIMH NIH HHS
  • NIAID NIH HHS

Cite

APA

Mgbako, O., Mehta, M., Dietz, D., Neidell, M. J., Huang, S. E., Zucker, J., Shoucri, S., Kubin, C. J., & Castor, D. (2023). Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City. Ethnicity and Disease. https://doi.org/10.18865/1653

Vancouver

Mgbako O, Mehta M, Dietz D, Neidell MJ, Huang SE, Zucker J, et al. Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City. Ethnicity and Disease. 2023. doi:10.18865/1653

BibTeX
@article{Mgbako2023,
  author = {Mgbako, Ofole and Mehta, Monica and Dietz, Donald and Neidell, Matthew J and Huang, Simian Esther and Zucker, Jason and Shoucri, Sherif and Kubin, Christine J and Castor, Delivette},
  title = {Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City},
  journal = {Ethnicity and Disease},
  year = {2023},
  doi = {10.18865/1653}
}
Start for free →